US010912801B2

(12) **United States Patent**
Kurtzberg et al.

(10) **Patent No.: US 10,912,801 B2**
(45) **Date of Patent: Feb. 9, 2021**

(54) **METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS**

(71) Applicant: **Duke University**, Durham, NC (US)

(72) Inventors: **Joanne Kurtzberg**, Durham, NC (US); **Geraldine Dawson**, Durham, NC (US); **Jesse Troy**, Durham, NC (US); **Jessica Sun**, Durham, NC (US)

(73) Assignee: **DUKE UNIVERSITY**, Durham, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/493,754**

(22) PCT Filed: **Mar. 13, 2018**

(86) PCT No.: **PCT/US2018/022174**

§ 371 (c)(1),
(2) Date: **Sep. 12, 2019**

(87) PCT Pub. No.: **WO2018/169952**

PCT Pub. Date: **Sep. 20, 2018**

(65) **Prior Publication Data**

US 2020/0069741 A1 Mar. 5, 2020

Related U.S. Application Data

(60) Provisional application No. 62/470,431, filed on Mar. 13, 2017.

(51) **Int. Cl.**

A61K 35/14	(2015.01)
A61K 35/51	(2015.01)
A61B 5/16	(2006.01)
A61P 43/00	(2006.01)
A61B 5/0476	(2006.01)
A61B 5/055	(2006.01)
A61B 5/00	(2006.01)
A61K 9/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 35/51*** (2013.01); ***A61B 5/0476*** (2013.01); ***A61B 5/055*** (2013.01); ***A61B 5/163*** (2017.08); ***A61B 5/4848*** (2013.01); ***A61K 9/0019*** (2013.01); ***A61P 43/00*** (2018.01)

(58) **Field of Classification Search**

CPC A61K 35/14

See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	01/66698	A1	9/2001
WO	05/024064	A2	3/2005
WO	14/018774	A1	1/2014

OTHER PUBLICATIONS

Dawson et al., "Autologous Cord Blood Infusions are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial", Stem Cells Translational Medicine, 2017, 6(5), 1332-1339.

(Continued)

Primary Examiner — Rosanne Kosson

(74) *Attorney, Agent, or Firm* — Polsinelli PC; Michelle L. McMullen; J. Wendy Davis

(57) **ABSTRACT**

The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

15 Claims, 4 Drawing Sheets